🇺🇸 FDA
Patent

US 10947198

Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents

granted A61KA61K31/352A61K31/382

Quick answer

US patent 10947198 (Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents) held by The Board of Regents for Oklahoma State University expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents for Oklahoma State University
Grant date
Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/352, A61K31/382, A61K31/47, A61P